Blue Flower

NOXXON is publicly traded on Paris’ Euronext Growth exchange (ALNOX.PA).

Company Information

NOXXON believes that the future of cancer treatment lies in finding optimal combinations of drugs to fight cancer in multiple ways.

NOXXON’s oncology-focused pipeline breaks the tumor protection barrier and blocks tumor repair by neutralizing chemokines in the tumor micro-environment (TME). NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 delivered final top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in September 2020 (read more here) and NOXXON will continue development of its pancreatic cancer Phase 2 program in collaboration with Merck (read more here). While awaiting the final read-out, encouraging interim data from the ongoing dose-escalation trial in chemotherapy refractory brain cancer patients have been published in June 2021 (read more here).